Pharmacochemical Strategies and Advances in Alzheimer's Disease Drug Development

Jie Chen

doi:10.54097/qbjryc26

Authors

Jie Chen

DOI:

https://doi.org/10.54097/qbjryc26

Keywords:

Alzheimer's disease, Pharmacochemical Strategies, pathological mechanism, Drug development.

Abstract

Alzheimer's disease (AD) is one of the diseases that seriously threaten human life and health. Currently, the exact pathological mechanism of the disease is still unknown, and there are no drugs that can terminate or reverse the pathological process, which have limited the discovery of AD-related targets and the development of drugs that can effectively treat AD. However, with the deepening research on the molecular mechanism of the disease and the development of computers and artificial intelligence, some potential targets of AD have been discovered and their structures have been analyzed, and at the same time, the paradigm of drug discovery and development by chemical means has been continuously expanded, which has provided medicinal chemists with a variety of methods and strategies for designing new compounds and thus synthesizing new small molecules that can be effective in treating AD. In this paper, we summarize four widely accepted hypotheses on the pathogenesis of AD and the medicinal chemistry strategies for small-molecule drug discovery and development, based on the new research results in recent years.

Downloads

Download data is not yet available.

References

[1] Li Ke, Liu Chong. Analysis of the Occurrence and Influential Factors of Psych behavioral Symptoms in Patients with Alzheimer's Disease. Journal of International Psychiatry, 2024, 51 (06): 1831 - 1835.

[2] 2024 Alzheimer's disease facts and figures. Alzheimers Dement, 2024, 20 (5): 3708 - 3821.

[3] Bi Danlei, Wen Lang, Xiong Wei, et al. Development of potential therapeutic targets of and approaches to Alzheimer disease. Chinese Journal of Pharmacology and Toxicology, 2015, 29 (04): 507 - 536.

[4] Sarsaiya S., Liu Bo, Jain A., et al. Advances in understanding prevention and treatment of alzheimer's disease: A comprehensive review. Journal of Zunyi Medical University, 2025, 48 (01): 77 - 97.

[5] Zhou Junyan, Jiang Xueyang, Feng Feng, et al. multi-target drug design strategy and its research progress. Acta Pharmaceutica Sinica, 2018, 53 (12): 2012 - 2025.

[6] Ashrafian H., Zadeh E. H., Khan R. H., Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation. International Journal of Biological Macromolecules, 2021, 167 (15): 382 - 394.

[7] Monteiro K. L. C., N. M. L. Freire, et al. BACE-1 inhibitors targeting Alzheimer’s disease. CurrAlzheimer Res, 2023, 20 (3): 131 - 148.

[8] Wojtunik-Kulesza K, M. Rudkowska, A. Orzeł-Sajdłowska. Aducanumab-Hope or Disappointment for Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24 (5): 4367.

[9] McDade E., J. L. Cummings, S. Dhadda, et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Research & Therapy, 2022, 14 (1): 191.

[10] Tell V, A. Hilgeroth. Recent developments of protein kinase inhibitors as potential AD therapeutics. Frontiers in Cellular Neuroscience, 2013, 19 (7): 189.

[11] Wang C, M. Terrigno, J. Li. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation. Neuron, 2023, 111 (17): 2660 - 2674.

[12] Islam M. R., M. A. Rabbi, T. Hossain. Mechanistic Approach to Immunity and Immunotherapy of Alzheimer's Disease: A Review. Acs Chemical Neuroscience, 2024.

[13] Theunis C, N. Crespo-Biel, V. Gafner, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy. PLoS One, 2013, 8 (8): e72301.

[14] Arranz A. M., B. De Strooper. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. Lancet Neurol, 2019, 18 (4): 406 - 414.

[15] Hansen D. V., J. E. Hanson, M. Sheng. Microglia in Alzheimer's disease. J Cell Biol, 2018, 217 (2): 459 - 472.

[16] Wang C., S. Zong, X. Cui, et al. The effects of microglia-associated neuroinflammation on Alzheimer's disease. Front Immunol, 2023, 22 (14): 1117172.

[17] Wang C, L. Fan, R. R. Khawaja, et al. Microglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathy. Nat Commun, 2022, 13 (1): 1969.

[18] Yin J, F. Zhao, J. E. Chojnacki, et al. NLRP3 Inflammasome Inhibitor Ameliorates Amyloid Pathology in a Mouse Model of Alzheimer's Disease. Mol Neurobiol, 2018, 55 (3): 1977 - 1987.

[19] Hamelin L, J. Lagarde, G. Dorothée, et al. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. Brain, 2016, 139 (Pt 4): 1252 - 64.

[20] Wang S, M. Mustafa, C. M. Yuede, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. J Exp Med, 2020, 217 (9): e20200785.

[21] Cao Junzheng, Song Junying, Wang Ruifang. Research progress on TREM2-mediated immune responses in Alzheimer's disease. Current Immunology, 2024, 44 (06): 526 - 529.

[22] Kandimalla R., P. H. Reddy. Therapeutics of Neurotransmitters in Alzheimer's Disease. Journal of Alzheimers Disease, 2017, 57 (4): 1049 - 1069.

[23] Yang Z, Y. Zou, L. Wang. Neurotransmitters in Prevention and Treatment of Alzheimer's Disease. Int J Mol Sci, 2023, 24 (4): 3841.

[24] Bi Danlei, Wen Lang, Xiong Wei, et al. Development of potential therapeutic targets of and approaches to Alzheimer disease. Chinese Journal of Pharmacology and Toxicology, 2015, 29 (04): 507 - 536.

[25] Gu Z, P. Zhong, Z. Yan. Activation of muscarinic receptors inhibits beta- amyloid peptide- inducedsignaling in cortical slices. J Biol Chem, 2003, 278 (19): 17546 - 17556.

[26] Gaonkar S. L., Y. Nadaf, D. Bilehal, et al. Industrially Scalable Synthesis of Anti-alzheimer Drug Donepezil. Asian Journal of Chemistry, 2017, 29 (9): 1999.

[27] Sarabia-Vallejo Á, P. López-Alvarado, J. C. Menéndez. Small-molecule theranostics in Alzheimer's disease. Eur J Med Chem, 2023, 255 (5): 115382.

[28] Li H., J. Wang, W. Zhang, et al. Functional Bioprobe for Responsive Imaging and Inhibition of Amyloid-β Oligomer Based on Curcuminoid Scaffold. Journal of Luminescence, 2021, 238: 118218.

[29] Liu Xueyan, Cha Daijun. The pathogenesis of Alzheimer's disease and the research progress of multi-target drugs based on pyran/pyranone scaffold. Journal of Fujian Medical University, 2022, 56 (05): 444 - 454.

[30] Dgachi Y, H. Martin, R. Malek, et al. Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy. J Enzyme Inhib Med Chem, 2019, 34 (1): 163 - 170.

[31] Carlier PR, D. M. Du, Y. Han, et al. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg Med ChemLett, 1999, 9 (16): 2335 - 2338.

[32] Jiang X. Y., T. K. Chen, J. T. Zhou, et al. Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery. ACS Med Chem Lett, 2018, 9 (3): 171 - 176.

[33] Suo Zongwu, Wei Kaixin, Xu Yi, et al. Research progress on natural products improving Alzheimer's disease by regulating neuroinflammation. Chinese Traditional and Herbal Drugs, 2023, 54 (7): 2284 - 2300.

[34] Chen R, Li X. J., Chen H. S., et al. Development of the “hid-den” multi-target-directed ligands by AChE / BuChE for the treat-ment of Alzheimer’s disease. Eur J Med Chem, 2023, 251: 115253.

[35] Koirala M, V. Karimzadegan, N. S. Liyanage, et al. Biotechnological Approaches to Optimize the Production of Amaryllidaceae Alkaloids. Biomolecules, 2022, 12 (7): 893.

[36] Xie Jun, Zhang Jingyi, Tang Ning, et al. Advances in biosynthesis of galanthamine and huperzine A. Chinese Traditional and Herbal Drugs, 2020, 51 (03): 812 - 820.

[37] BARTON D. H. R., G. W. KIRBY. Phenol Oxidation and Biosynthesis.: Part V. The Synthesis of Galanthamine. Journal of the Chemical Society, 1962.

[38] Wang Wei, Jiang Fang, Zhu Wentao, et al. Study on chem-enzymatic synthesis of (-)-galanthamine. Chinese Journal of Medicinal Chemistry, 2022, 32 (12): 909 - 914.

[39] Liu Tao, Qian Chao, Chen Xinzhi. Research on total synthesis of racemic galanthamine. Journal of Zhejiang University (Engineering Science), 2006, (3): 520 - 523.

[40] Gao Ting, Song Qi, Qiu Yinhua, et al. Synthesis of Important Intermediate Bromonarwedine of Galantamine. Chinese Journal of Synthetic Chemistry, 2012, 20 (2): 251 - 253.

[41] Ren Shuyue, Sun Lan, Du Guanhua. Advances in the study of repositioning strategies in the application of therapeutic agents for rare diseases. Journal of Jiangsu University (Medicine Edition), 2021, 31 (01): 17 - 22.

[42] Zhou You, Xue Xin, Wang Lei, et al. Discovery of New Cholinesterase Inhibitors Based on the Database of FDA-Approved Drugs. Journal of Southwest University (Natural Science Edition), 2022, 44 (12): 60 - 69.

[43] Zeng H., Wu X. Alzheimer's disease drug development based on Computer-Aided Drug Design. Eur J Med Chem, 2016, 121 (4): 851 - 863.

[44] Qin Han, Luo Meidi, Wang Siyuan, et al. Design, synthesis and neuroprotective effect of thiol HDAC6 inhibitors containing pyrazolformamide. Chinese Journal of Medicinal Chemistry, 2024, 34 (06): 421 - 433.

[45] Yao M, G. W. Miller, B. N. Vardarajan, et al. Deciphering proteins in Alzheimer's disease: A new Mendelian randomization method integrated with AlphaFold3 for 3D structure prediction. Cell Genom. Cell Genomics, 2024, 4 (12): 100700.